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Background: The effectiveness of the currently available box jellyfish (Chironex fleckeri) antivenom has been subject of
debate for many years. To assess whether the box jellyfish antivenom has the ability to attenuate venom-induced damage
at cellular level, the present study analyzed the dose and time dependence of the antivenom in a cell-based assay.
Methods: Different doses of antivenom were added to venom and subsequently administered to cells and the cell index
was measured using xCelligence Technology (ACEA Biosciences). Similarly, antivenom and venom were incubated over
different time periods and cell survival measured as stated above. For both experiments, the cell index was plotted as a
measure of cell survival against the dose or incubation time and significance was determined with the use of a one-way
ANOVA with a LSD post hoc test.
Results: Increasing concentrations of antivenom significantly augmented cell survival, with a concentration of
approximately five times the currently recommended dose for human envenomation, causing the first significant increase
in cell survival compared venom alone. Further, cell survival improved with increasing incubation time of venom and
antivenom prior to addition to the cells, indicating that box jellyfish antivenom requires approximately 70 minutes to
neutralize C. fleckeri venom.
Conclusion: The presented results suggest that the currently recommended dose of antivenom requires adjustment, and
more importantly, a human trial to test the effects of higher concentrations is also necessary. Further, antivenom has
delayed neutralizing effects (i.e. after 70 minutes) which underlines the eminence of immediate and prolonged
cardiopulmonary resuscitation in victims suffering from a C. fleckeri venom-induced cardiovascular collapse.
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The Commonwealth Serum Laboratories™ (CSL) have
been producing box jellyfish antivenom, raised from ovine
antibodies since the 1970s [1]. Currently, Chironex fleckeri
envenomation victims are commonly given CSL anti-
venom via intramuscular injection and there are several
reports of pain amelioration as well as successful recovery
of severely envenomed patients following its administra-
tion [2,3]. However, since C. fleckeri venom is distributed
through the vascular system, it potentially leads to rapid
cardiovascular collapse. Thus, intramuscular (versus intra-
venous) route has been criticized as an adequate via of ad-
ministration [2]. In addition, there have been reports of* Correspondence: athena.andreosso@my.jcu.edu.au
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article, unless otherwise stated.severe envenomed victims dying despite (as well as some
surviving without) the administration of antivenom, which
question its effectiveness as well as its necessity [3-6].
Experimental evidence in vitro and in vivo also shows
conflicting results. On one hand, it has been suggested
that the venom extraction method influenced the effect-
iveness of antivenom. For example, the venom currently
used for the serum production is obtained by an extrac-
tion method developed by Barnes [7] called “milking”. In
this technique, jellyfish tentacles from C. fleckeri are
placed on an amniotic membrane that is tensioned over a
jar and through subsequent mechanical, chemical or sonic
stimulation the nematocysts are prompted to deliver
venom through the membrane into the collection jar [7].
Accordingly, prophylactic administration of antivenom
significantly delayed death in mice injected with “milked”
venom. However, the effects of one toxic agent in venomtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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could not be neutralized [8]. Conversely, antivenom raised
from antibodies against both, milked and native venom,
was able to prevent cardiovascular collapse in rats [9].
While it generally seems that CSL antivenom has the
ability to attenuate venom effects, relatively high doses
are required to achieve venom neutralization [9]. It has
thus been suggested that the current initial treatment
for human envenomation (one to three vials, i.e., 20,000-
60,000 units) may be insufficient [9-11]. Further complica-
tions regarding the use and effectiveness of the antivenom
exist with only prophylactic administrations being able to
counteract the venom effects, which suggests that the
antivenom is also too slow to attenuate the effects of
C. fleckeri venom in a clinically relevant setting [10,12].
In the light of this, the present study analyses the dose
and time dependence of CSL box jellyfish antivenom using
a cell-based assay to create dose–response curves for anti-
venom per se, as well as for different venom-antivenom
incubation times. Considering that currently there are
no generally reliable treatments available, the results of
the present study may have implications for the produc-




Adult specimens of C. fleckeri were collected near
Napranum, Qld, Australia (12.6835° S, 141.8884° E) in
November 2011; tentacles were removed and nematocysts
were collected according to Bloom et al. [13]. Venom ex-
traction was carried out following the method of Carrette
and Seymour [14]. In short, lyophilized nematocysts were
put into 3-mL vials with approximately 5 mm (height) of
glass-beads and filled with Milli-Q-water (MQ) (at 4°C).
The mixture was then shaken at 5,000 rpm in a bead mill
beater ten times for two minutes to maximize nemato-
cyst rupture and venom yield. After each time in the
beater the vials were placed in ice slurry for five mi-
nutes. Finally, the mixture was centrifuged for one mi-
nute (13,000 rpm); the supernatant (i.e. venom) was
collected and subsequently lyophilized. The lyophilized
venom was then stored at −80°C until required for use.
Reconstituted venom was placed in slurry ice baths to
preserve toxic activity of venom samples that were rehy-
drated for experimental procedures.
Cell culture and Xcelligence system
Human cholangiocarcinoma cells (KKU-100 cell line,
hereafter referred to as cancer cells) were cultured follow-
ing the manufacturer’s instructions in 5 mL RPMI media
(Gibco) with 10% fetal bovine serum at 37°C and 5% CO2
in 25 cm2 monolayer flasks. The cells were seeded and in-
cubated in 96-E-well plates (ACEA Biosciences) atapproximately 6,000 cells in 150 mL media per well for
24 hours at 37°C and 5% CO2 to allow the cells to attach
to the bottom of the wells before treatment was applied.
Cell adherence to the bottom of the plate, i.e. the cell
index (CI), a measure of cell viability was monitored using
xCELLigence system [15].
Venom
Venom from C. fleckeri at a concentration of 1.47 μg/mL
was used for all experiments as it induced approximately
70% death of cancer cells in ten minutes.
Antivenom
Antivenom (batch: 0556–07301; expiry: 08/2015) con-
centrations were converted from volume concentration
(μL/mL) to units per volume (units/mL) to allow for com-
parison with previous studies. Further, the currently rec-
ommended dose of one to three vials (i.e. 20,000-60,000
units) for one average adult (approx.70 kg) has been calcu-
lated into units per volume as follows. A 70 kg adult has a
blood volume of approximately 4700 mL, of which only
55% is plasma (45% blood cells), thus one vial (20,000
units) of antivenom is administered to approximately
2585 mL (plasma volume) resulting in 7.7 units/mL (15.4
or 23.30 units/mL for two or three vials respectively) of
antivenom in the vascular system (if given intravenously).
For the dose–response curve experiment, antivenom
concentrations of 0–205.10 units/mL were used. Con-
cerning incubation time, an antivenom concentration of
134.23 units/mL was incubated with venom (0–135 mi-
nutes), as this represented a concentration at which the
venom had a clear effect on cell survival (50%). This
allowed for all possible outcomes of venom-antivenom in-
cubation effects: increased, unchanged and decreased cell
survival.
Dose–response curve and incubation time
For the dose–response curve, three replicates of each of
the different concentrations of antivenom were mixed
with the venom just before adding the mixture (20 μL)
to the cells in the xCelligence plate. Additionally, a control
with venom (but no antivenom), one with antivenom only
and one with MQ-water (used for the dilutions) only were
added to the cells in three replicates, each. The dose–
response curve was then generated with the use of Prism
(GraphPad Software), in brief, to analyze if there was a
dose-dependent relationship, antivenom concentrations
were plotted against cell survival.
Similarly, to test the effects of different venom-antivenom
incubation times on cell survival three replicates of venom
were incubated with antivenom over different periods of
time (0, 2.5, 5, 10, 15, 20, 30, 40, 50, 60, 75 and 135 minutes)
at 37°C (representing an approximate for the human body
temperature). For this experiment, additionally to the above
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bated replicates (20 μL) of each control were added to
the cells. The data for nearly four hours post-treatment
addition were then plotted and analyzed in Prism. All
figures were normalized to the cell index of the control
(MQ for the antivenom-dose–response curve and incu-
bated MQ for incubation time experiment), which was set
to 100% cell survival. For both experiments a one-way
ANOVA with an LSD post hoc test was used to test for
significant concentration- and incubation-time dependent
increases in cell survival.
Results
Dose–response curve
Cell survival increased significantly with higher doses of
antivenom (F15,2 = 38.901, p < 0.001) (Figure 1), thus
clearly showing a dose-dependent relationship between
antivenom concentrations and cell survival. The first
concentration to have a significant effect on cell survival,
relative to the control, was 134.24 units/mL, resulting in
approximately 50% cell survival (LSD post hoc). This con-
centration is approximately a fivefold higher than the max-
imal recommended initial dose (three vials, i.e. 23.1 units/
mL) for C. fleckeri envenomed humans. Concentrations
higher than 180 units/mL resulted in nearly 100% survival
of the cells, despite exposure to venom (1.47 μg/mL) and
resulted in significantly higher cell survival than concentra-
tions below 145 units/mL (LSD post hoc).
Incubation time
Increasing incubation time had a significant effect on
cell survival (F12,2 = 3.29, p = 0.008) (Figure 2). The first




















Figure 1 Dose–response curve of C. fleckeri antivenom against a 1.47
to the cells. The error bars represent 95% CI for each mean (three replicat
one, two and three vials – is indicated (a, b and c, respectively) for referencvenom-antivenom incubation time of 70 minutes (LSD
post hoc). Thus at a venom concentration of 1.47 μg/mL
it took the antivenom (156.41 units/mL) approximately
70 minutes to effectively neutralize the venom effects,
resulting in approximately 100% cell survival.
Discussion
This is the first study presenting a dose–response curve
for the commercially available CSL box jellyfish antivenom
in a cell-based assay. The presented results clearly indicate
that the effectiveness of the antivenom is dose-dependent,
with higher concentrations of antivenom resulting in
higher protective effects on cell survival. Similarly, a previ-
ous cell-based study using prophylactic antivenom con-
centrations between 0.04 and 5 units/mL on A7r5 cells
(1 μg/mL of venom), found that concentrations below 5
units/mL are ineffective on cell survival [10]. Although the
latter study used a different cell type, as well as lower
venom and antivenom concentrations, the benefit of
higher doses of antivenom is clear.
Similarly, in vivo studies reported that venom only
(30 μg/kg, i.e. for an human adult approx. 2100 μg/70 kg,
thus approx. 0.81 μg/mL blood plasma) premixed with
3,000 units/kg of antivenom (ca. 10.5 vials for a 70 kg
adult) was able to inhibit cardiovascular collapse in anes-
thetized rats, whereas concentrations of 1,000 units/kg
and 600 units/kg (ca. 3.5 and 2.1 vials per 70 kg adult)
failed to do so [9]. These results slightly contradicted a
previous study in which the same antivenom (3,000 units/
kg) and venom dose (approx. 0.81 μg/mL) were used, yet,
the majority of the anesthetized rats (60%) suffered fatal
cardiovascular collapse [16]. However, with MgSO4 as ad-
junct treatment all test animals survived [16].150 200 250
tration [units/ml]
μg/mL of venom for three hours and 50 minutes after exposure
es). The currently recommended dose for human envenomation – of
e.
Figure 2 Effect of incubation time of C. fleckeri antivenom (156.41 units/mL) with venom (1.47 μg/mL) on cell survival at three hours
and 50 minutes after exposure to the cells. The error bars represent 95% CI for each mean (three replicates).
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trations and thereby venom deactivation was successful
(with an antivenom dose of 180 units/mL, i.e. 23.5 vials/
adult), thus suggesting that the currently recommended
dose for human envenomation (three vials) is probably
insufficient. Recurrent criticism as to the general ability
of antivenom to reduce the effects of C. fleckeri toxins
may well be justified, yet not due to the serum being un-
able to neutralize the venom as a recent immunoaffinity
assay suggested. The study was originally designed to con-
sider differences between antibodies raised against milked,
i.e. CSL-antivenom, and native venom. It has demon-
strated that compared to polyclonal rabbit IgG antibodies
raised against native venom, the commercially available
CSL-antivenom indeed contains all the necessary anti-
bodies to the main toxic agents in C. fleckeri venom [9].
However, since CSL has announced their recommenda-
tion for an initial dose of one to three vials of antivenom
for human envenomation, it has been discovered that
C. fleckeri venom undergoes an ontogenetic shift from
invertebrate- to vertebrate-specificity with adult (as op-
posed to young) animals being more toxic to humans [17].
Further, the geographic location is now known to also affect
the toxicity of the venom [18]. Consequently, the age and
collection location of the specimens used to obtain the
venom to raise the antibodies may affect the potency of the
antivenom. Additionally, accurate quantification of venom
injected into a victim is improbable, since the magnitude of
envenomation depends on the degree of tentacle contact,
and thus conclusions on adequate doses of antivenom for
human envenomation may be inaccurate.In the present study, the period of incubation of C. fleck-
eri venom with antivenom also influenced its effectiveness
regarding cell survival, which suggests that antivenom is
not only dose- but also time-dependent. Considering that
initial beachside emergency treatment for C. fleckeri en-
venomation currently recommends intramuscular admin-
istration of three vials (each 20,000 units/6.25 mL), this
administration route may be slow and the dose small to
attenuate venom effects. In most cases of severe C. fleckeri
envenomation the venom is distributed through the vascu-
lar system, thus reaching its target tissue, the heart, within
minutes [2]. In fatally envenomed victims death may occur
in less than ten minutes (usually within 20 minutes) after
contact with C. fleckeri tentacles [4,19-21].
In the present study, it took more than 60 minutes to
antivenom to neutralize the venom. With intramuscular
injection of antivenom, delivery of the treatment would be
further inhibited, since it would also have to pass through
the lymphatic system in order to reach the heart and
inhibit cardiovascular collapse. Conversely, if intravenous
injection of antivenom could be administered as soon
as possible, and life saving measures such as cardiopul-
monary resuscitation could be undertaken unceasingly
(as required by the victim), the antivenom would show its
beneficial effects earlier. However, this partially implies
that the effects of the venom are reversible (including that
venom already bound to cells can be neutralized), which
may contradict the currently believed pore-forming mode
of action [2,12,22]. Finally, in the light of the rapid on-
set of symptoms and the fact that experimentally only
prophylactic doses of antivenom were effective, the window
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too short [16,19]. However, this cannot be assumed until
higher initial doses have been tried.
Conclusion
The present study is the first to create a dose–response
curve and to compare different incubation times for CSL
antivenom and all evidence suggests that the potential for
venom neutralization is absolutely apparent. However,
current recommended doses (three vials) seem far too
small and thus need to be adjusted. At higher doses, anti-
venom appeared to also improve its neutralizing ability
with incubation time, thus suggesting that the venom-
antivenom binding may be a process ongoing for just
about over one hour. Thus, chances for successful treat-
ment following a C. fleckeri envenomation may improve if
the concentration of antivenom as well as the given dose
are increased and the life saving measures are exception-
ally prolonged in order to provide time for the antivenom
act on the venom.
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